Xencor Inc
NASDAQ:XNCR

Watchlist Manager
Xencor Inc Logo
Xencor Inc
NASDAQ:XNCR
Watchlist
Price: 25.42 USD -2.46% Market Closed
Market Cap: 1.8B USD
Have any thoughts about
Xencor Inc?
Write Note

Xencor Inc
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Xencor Inc
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Xencor Inc
NASDAQ:XNCR
Current Portion of Long-Term Debt
$7.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Current Portion of Long-Term Debt
$12.6B
CAGR 3-Years
24%
CAGR 5-Years
19%
CAGR 10-Years
89%
Gilead Sciences Inc
NASDAQ:GILD
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Current Portion of Long-Term Debt
$3.5B
CAGR 3-Years
-6%
CAGR 5-Years
12%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Xencor Inc
Glance View

Market Cap
1.8B USD
Industry
Biotechnology

Xencor, Inc. is biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. The company is headquartered in Monrovia California, California and currently employs 254 full-time employees. The company went IPO on 2013-12-03. The firm is advancing a portfolio of clinical-stage XmAb drug candidates from its protein engineering technology platforms. The firm uses its engineering capabilities to enable its understanding of protein structure and interactions to design technologies and XmAb development candidates with properties. The company is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Tidutamab, XmAb841, XmAb306, AMG 509, XmAb819, XmAb104, XmAb564 and Novartis XmAb.

XNCR Intrinsic Value
16.35 USD
Overvaluation 36%
Intrinsic Value
Price

See Also

What is Xencor Inc's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
7.7m USD

Based on the financial report for Sep 30, 2024, Xencor Inc's Current Portion of Long-Term Debt amounts to 7.7m USD.

Back to Top